Less than 10 years later, the small-molecule kinase inhibitors vemurafenib and dabrafenib were approved for use in BRAF mutation-positive melanomas, as the front-runners in a competition between numerous companies engaged in cancer drug discovery (Bollag et al, 2012; Hauschild et al, 2012). Here, BRAF is linked to melanoma.